Nine More Years? Sandoz Loses Again On Enbrel Biosimilar

Sandoz Has Held FDA Approval For Its Erelzi Version Since 2016

 
• By Dean Rudge

Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.

2029_Ice
Sandoz' biosimilar etanercept launch plans may be on ice until 2029 • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin